Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537936 | 0.76 | USP2 (0.33) | — | |
| SCHEMBL18095036 | 0.74 | — | — | |
| SCHEMBL5960757 | 0.74 | — | — | |
| SCHEMBL2057170 | 0.72 | — | — | |
| SCHEMBL17466334 | 0.72 | PREP (0.31) | — | |
| SCHEMBL5231067 | 0.71 | — | — | |
| SCHEMBL11349376 | 0.71 | CA2 (0.47) | CA2 | |
| Trifluoromethanesulfonic Acid SCHEMBL20704373 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL8719772 | 0.69 | — | — | |
| SCHEMBL2057864 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091491-B2 | Silylamine compound and latent curing agent comprising said silylamine compound | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| CN-112930352-B | Silylamine compounds and latent curing agents containing the same | 广荣化学株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-20220119583-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3875461-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | Koei Chemical Company, Limited (JP) | 2021-09-08 | — | — | EP | disclosed |
| CN-112930352-A | Silylamine compound and latent curing agent containing the same | 广荣化学株式会社 | 2021-06-08 | — | — | CN | disclosed |
| CN-1274344-A | Novel vitamin D analogues | LEO PHARMACEUTICAL PRODUS LTD (DK) | 2000-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119583-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | CDKN1A, SIRT2, H1-4 | CA2 994/4885 |
| US-12091491-B2 | Silylamine compound and latent curing agent comprising said silylamine compound | CDKN1A, SIRT2, H1-4 | CA2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.